Literature DB >> 17070589

Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Xiaoling Liang1, Defen Shen, Yongsheng Huang, Chunyue Yin, Christine M Bojanowski, Zhengping Zhuang, Chi-Chao Chan.   

Abstract

PURPOSE: The surgical excision of retinal vascular lesions including hemangioblastomas is rarely practiced. This study investigates the pathological characteristics of 4 patients (3 with von Hippel-Lindau [VHL] disease and 1 with a vasoproliferative retinal tumor) who underwent ocular tumor resection. von Hippel-Lindau is an autosomal dominant disease caused by a defect of the VHL tumor suppressor gene. The VHL protein is required for oxygen-dependent degradation of hypoxia-inducible factor 1alpha. This factor regulates vascular endothelial growth factor (VEGF) and the chemokine receptor CXCR4. Retinal hemangioblastoma is the most common tumor observed in VHL disease. We investigated the expression of CXCR4; its ligand, CXCL12/SDF-1alpha; VEGF; and the VHL gene in VHL disease-associated retinal hemangioblastomas.
DESIGN: Interventional case series with immunohistological and molecular pathological analyses. PARTICIPANTS: Immunohistochemistry and molecular pathology of the surgically excised retinal lesions were performed. INTERVENTION: Large retinal hemangioblastomas (1-3 disc diameters) and vasoproliferative tumors were resected surgically after laser photocoagulation in 4 patients. The excised tissues were snap frozen and evaluated by histology. Molecular pathology was performed for the VHL gene, and immunohistochemistry and molecular detection (reverse transcription polymerase chain reaction) were carried out for VEGF, CXCR4, and CXCL12. MAIN OUTCOME MEASURES: Evaluation of clinical presentations and molecular pathology of the excised retinal lesions.
RESULTS: Large retinal hemangioblastomas were resected successfully from the 3 VHL cases. Postoperatively, all patients were stable. Molecular analyses disclosed the loss of heterozygosity at the VHL allele locus in the VHL retinal hemangioblastomas but not in the vasoproliferative tumor. High levels of transcript and protein were found for VEGF and CXCR4, whereas low levels of CXCL12 mRNA were expressed in the retinal hemangioblastomas associated with VHL disease. In contrast, very low levels of VEGF and CXCR4 mRNA were detected in the vasoproliferative tumor. Furthermore, increased expression of VEGF and CXCR4 was detected in more active hemangioblastomas.
CONCLUSIONS: Surgical resection of large retinal hemangioblastomas may be useful for therapy in selected VHL patients. Activated VHL lesions produce more VEGF. This is the first demonstration of CXCR4 expression in VHL disease-associated retinal hemangioblastomas. We suggest targeting CXCR4 as an additional therapeutic strategy for VHL disease-associated retinal hemangioblastomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070589      PMCID: PMC2147685          DOI: 10.1016/j.ophtha.2006.05.068

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  53 in total

Review 1.  The brightening future of HIV therapeutics.

Authors:  Warner C Greene
Journal:  Nat Immunol       Date:  2004-09       Impact factor: 25.606

Review 2.  [Retinal angiomatosis].

Authors:  D Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2005-02       Impact factor: 0.700

3.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Clinicopathologic correlation of argon laser photocoagulation of retinal angiomas in a patient with von Hippel-Lindau disease followed for more than 20 years.

Authors:  R H Rosa; M F Goldberg; W R Green
Journal:  Retina       Date:  1996       Impact factor: 4.256

Review 5.  Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells.

Authors:  Magda Kucia; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Biol Cell       Date:  2005-02       Impact factor: 4.458

6.  VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.

Authors:  C C Chan; A O Vortmeyer; E Y Chew; W R Green; D M Matteson; D F Shen; W M Linehan; I A Lubensky; Z Zhuang
Journal:  Arch Ophthalmol       Date:  1999-05

7.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

8.  Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma.

Authors:  K M Kreusel; N Bornfeld; A Lommatzsch; A Wessing; M H Foerster
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

Review 9.  Clinical features and molecular genetics of Von Hippel-Lindau disease.

Authors:  E R Maher; A R Webster; A T Moore
Journal:  Ophthalmic Genet       Date:  1995-09       Impact factor: 1.803

10.  Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment.

Authors:  H R McDonald; H Schatz; R N Johnson; G W Abrams; G C Brown; A J Brucker; D P Han; H Lewis; W F Mieler; S Meyers
Journal:  Ophthalmology       Date:  1996-02       Impact factor: 12.079

View more
  12 in total

1.  Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma.

Authors:  Yujuan Wang; Mones S Abu-Asab; Defen Shen; Zhengping Zhuang; Emily Y Chew; Chi-Chao Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-24       Impact factor: 3.117

Review 2.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

Review 3.  Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.

Authors:  Stanley Park; Chi-Chao Chan
Journal:  Histol Histopathol       Date:  2012-08       Impact factor: 2.303

Review 4.  Systemic VHL gene functions and the VHL disease.

Authors:  Hannah L Bader; Tien Hsu
Journal:  FEBS Lett       Date:  2012-04-25       Impact factor: 4.124

5.  Ocular clusterin expression in von Hippel-Lindau disease.

Authors:  Min Zhou; Defen Shen; James E Head; Emily Y Chew; Patricia Chévez-Barrios; W Richard Green; Chi-Chao Chan
Journal:  Mol Vis       Date:  2007-11-15       Impact factor: 2.367

6.  Expression of inhibin alpha by stromal cells of retinal angiomas excised from a patient with von Hippel-Lindau disease.

Authors:  Akiko Miyazawa; Makoto Inoue; Akito Hirakata; Annabelle A Okada; Kuniko Iihara; Yasunori Fujioka
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

Review 7.  Biopsy techniques and yields in diagnosing primary intraocular lymphoma.

Authors:  John A Gonzales; Chi-Chao Chan
Journal:  Int Ophthalmol       Date:  2007-04-18       Impact factor: 2.031

8.  Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Authors:  Roeliene C Kruizinga; Denise M S van Marion; Wilfred F A den Dunnen; Jan C de Groot; Eelco W Hoving; Sjoukje F Oosting; Hetty Timmer-Bosscha; Rosalie P H Derks; Chantal Cornelissen; Rob B van der Luijt; Thera P Links; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

9.  Comparison of Current Optical Coherence Tomography Angiography Methods in Imaging Retinal Hemangioblastomas.

Authors:  Michael Reich; Andreas Glatz; Daniel Boehringer; Charlotte Evers; Moritz Daniel; Felicitas Bucher; Franziska Ludwig; Simone Nuessle; Wolf A Lagrèze; Peter M Maloca; Clemens Lange; Thomas Reinhard; Hansjuergen Agostini; Stefan J Lang
Journal:  Transl Vis Sci Technol       Date:  2020-07-08       Impact factor: 3.283

Review 10.  Ocular Manifestations of von Hippel-Lindau Disease.

Authors:  Misty D Ruppert; Meredith Gavin; Kelly T Mitchell; Alan N Peiris
Journal:  Cureus       Date:  2019-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.